Free Trial
OTCMKTS:SIGY

Sigyn Therapeutics 4/15/2025 Earnings Report

Sigyn Therapeutics logo
$2.76 -0.99 (-26.40%)
As of 10/3/2025 03:51 PM Eastern

Sigyn Therapeutics EPS Results

Actual EPS
-$2.51
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Sigyn Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Sigyn Therapeutics Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Sigyn Therapeutics Earnings Headlines

Nvidia Times 1,000,000
Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 trillion calculations per second. Elon Musk and Nvidia’s Jensen Huang are now teaming up to deploy one million of these chips inside what could become the most advanced AI machine on the planet. But according to James Altucher, the real opportunity isn’t in Tesla or Nvidia. He’s uncovered a little-known company that Musk, Nvidia, and even 98% of the Fortune 500 already rely on to make AI 2.0 possible. Nvidia’s CEO has even called this company “essential” to their expansion.tc pixel
Sigyn Therapeutics Announces Cardiovascular Disease Study
See More Sigyn Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sigyn Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sigyn Therapeutics and other key companies, straight to your email.

About Sigyn Therapeutics

Sigyn Therapeutics (OTCMKTS:SIGY), a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats. The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. In addition, it develops ChemoPrep to enhance the tumor site delivery of chemotherapy; ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis; and ImmunePrep to enhance the potential efficacy of immunotherapeutic antibodies. Sigyn Therapeutics, Inc. was founded in 2019 and is headquartered in San Diego, California.

View Sigyn Therapeutics Profile

More Earnings Resources from MarketBeat